Literature DB >> 22242554

Simultaneous surgery for primary colorectal cancer and metastatic lesions?

Bengt Gustavsson1.   

Abstract

Approximately 20-25% of patients with colorectal cancer present with liver metastases at the time of diagnosis. Traditionally, resection of the primary tumor has been advocated in order to prevent complications of the primary tumor colorectal cancer in patients with synchronous liver metastases. The published data concerning long-term prognosis in this group of patients are discordant. Although some of the reports show survival benefits from resection of the primary tumor, these studies are retrospective with small number of patients and using single drug chemotherapy. For patients with resectable liver metastases, new studies indicate that progression-free survival is best in patients receiving perioperative chemotherapy. In patients with synchronous nonresectable liver metastases and colorectal cancer, there is no published prospective randomized study comparing initial surgery of the primary tumor with neoadjuvant chemotherapy. However, recent publications show that in patients receiving chemotherapy based on oxaliplatin or irinotecan combined with targeted treatments, the complications associated with the primary tumor are less than 10%. The conclusion should be that today prophylactic surgery of asymptomatic primary colorectal cancer in patients with liver metastases cannot be recommended.

Entities:  

Mesh:

Year:  2012        PMID: 22242554     DOI: 10.3109/00365521.2012.640824

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  3 in total

1.  Conversion therapy combined with individualized surgical treatment strategy improves survival in patients with colorectal cancer liver metastases.

Authors:  Rui Ma; Tao Li
Journal:  Int J Clin Exp Pathol       Date:  2021-03-01

Review 2.  Systematic review of resecting primary tumor in MNETs patients with unresectable liver metastases.

Authors:  Jingfei Guo; Qian Zhang; Xinyu Bi; Jianguo Zhou; Zhiyu Li; Zhen Huang; Yefan Zhang; Muxing Li; Xiao Chen; Xuhui Hu; Chi Yihebali; Junbo Liang; Jianmei Liu; Jianjun Zhao; Jianqiang Cai; Hong Zhao
Journal:  Oncotarget       Date:  2017-03-07

3.  Mindin serves as a tumour suppressor gene during colon cancer progression through MAPK/ERK signalling pathway in mice.

Authors:  Xiao-Shen Cheng; Ya-Ni Huo; Yan-Yun Fan; Chuan-Xing Xiao; Xiao-Mei Ouyang; Lai-Ying Liang; Ying Lin; Jian-Feng Wu; Jian-Lin Ren; Bayasi Guleng
Journal:  J Cell Mol Med       Date:  2020-07-02       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.